Swedish Biotech Atrogi Doses First Subjects in ATR-258 Trial, Focusing on Muscle Preservation in Obesity Treatment
Stockholm-based clinical-stage biotechnology company Atrogi AB has begun dosing participants in a new human trial evaluating its lead drug candidate, ATR-258. The study centers on a critical, often overlooked aspect of weight loss: preserving muscle mass. As the obesity drug market evolves, Atrogi aims to differentiate itself by developing a therapy that not only reduces fat but also maintains and potentially enhances muscle function.
The Challenge of Weight Loss and Muscle Loss
Recent advancements in obesity treatments have brought powerful new therapies to market, but these often come with a complex reality. While effective at reducing overall weight, some weight loss can be muscle loss, particularly concerning for older adults. Loss of muscle can lead to decreased strength, reduced resilience, and a diminished quality of life. Atrogi’s approach seeks to address this issue directly.
How ATR-258 Works
ATR-258 is an oral therapy designed to mimic some of the metabolic and muscle-related benefits of exercise. The drug is a first-in-class oral β2-adrenergic receptor agonist, which precisely activates skeletal muscle metabolism through a novel signaling pathway. This approach aims to enhance glucose uptake and improve body composition by reducing fat and preserving lean muscle, potentially without the cardiovascular risks associated with traditional β2-agonists. Atrogi describes ATR-258 as having the potential to drive fat loss, increase muscle, and improve metabolism.
The Current Trial and Research Backing
The ongoing trial, an 8-week, investigator-initiated interventional study, is evaluating the effects of ATR-258 on muscle in overweight male volunteers. The study is led by Associate Professor Morten Hostrup of the University of Copenhagen, who will examine how ATR-258 affects human skeletal muscle through daily oral dosing. This research builds on a landmark study published in Cell in June 2025, which validated Atrogi’s platform and demonstrated the potential of ATR-258.
Prior to this trial, a Phase 1 safety study completed in 2025 showed that ATR-258 was safe and well-tolerated in both healthy volunteers and individuals with type 2 diabetes.
Beyond Obesity: A Muscle-Health and Longevity Thesis
Atrogi’s vision extends beyond obesity treatment. The company is exploring the potential of ATR-258 to address muscle-wasting conditions such as immobilization, aging, and weight loss. This broader focus positions Atrogi within the growing field of longevity research, which emphasizes maintaining physical function and quality of life as people age. The company anticipates sharing the results of the current trial later in 2026.
Expert Perspectives
Professor Tore Bengtsson, founder and chief scientific officer of Atrogi, highlighted the significance of Hostrup’s involvement and the strength of the scientific foundation supporting ATR-258. Paul Little, Atrogi’s chief executive officer, called the first dosing “an important milestone” and emphasized the potential of the resulting data to support the drug’s development across various metabolic and muscle-wasting conditions.
While acknowledging the early stage of development and the inherent challenges of “exercise mimetics,” industry observers suggest Atrogi’s timing is strategic. The obesity market is shifting towards therapies that prioritize not just weight loss, but also the preservation of muscle mass and overall metabolic health.